Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 14, 2004 - Issue 4
Submit an article Journal homepage
211
Views
31
CrossRef citations to date
0
Altmetric
Review

KCNQ potassium channels: drug targets for the treatment of epilepsy and pain

Alan D Wickenden Icagen, Inc, Suite 460, 4222 Emperor Boulevard, Durham, NC 27703, USA. [email protected]
,
Rosemarie Roeloffs Icagen, Inc, Suite 460, 4222 Emperor Boulevard, Durham, NC 27703, USA. [email protected]
,
Grant McNaughton-Smith Icagen, Inc, Suite 460, 4222 Emperor Boulevard, Durham, NC 27703, USA. [email protected]
&
Greg C Rigdon Icagen, Inc, Suite 460, 4222 Emperor Boulevard, Durham, NC 27703, USA. [email protected]
Pages 457-469 | Published online: 22 Apr 2005

Bibliography

  • EISENBERG E, LURIE Y, BRAKER C, DAOUD D, ISHAY A: Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology (2001) 57:505–509.
  • BIERVERT C, SCHROEDER BC, KUBISCH C et al.: A potassium channel mutation in neonatal human epilepsy. Science (1998) 279:403–406.
  • ••One of three papers describing thediscovery of KCNQ2/3 and their linkage to neonatal epilepsy.
  • CHARLIER C, SINGH NA, RYAN SG et al.: A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat. Genet. (1998) 18:53–55.
  • ••One of three papers describing thediscovery of KCNQ2 /3 and their linkage to neonatal epilepsy.
  • SINGH NA, CHARLIER C, STAUFFER D et al.: A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat . Genetics (1998) 18:25–29.
  • ••One of three papers describing thediscovery of KCNQ2 /3 and their linkage to neonatal epilepsy
  • SINGH NA, WESTENSKOW P, CHARLIER C et al.: KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum. Brain. (2003) Oct 8 [Epub ahead of print].
  • COPPOLA G, CASTALDO P, MIRAGLIA DEL GIUDICE E et al: A novel KCNQ2 KMchannel mutation in benign neonatal convulsions and centrotemporal spikes. Neurology (2003) 61:131–134.
  • DEDEK K, FUSCO L, TELOY N, STEINLEIN OK: Neonatal convulsions and epileptic encephalopathy in an Italian family with a missense mutation in the fifth transmembrane region of KCNQ2. Epilepsy Res. (2003) 54:21–27.
  • DEDEK K, KUNATH B, KANANURA C, REUNER U, JENTSCH TJ, STEINLEIN OK: Myokymia and neonatal epilepsy caused by a mutation in the voltage sensor of the KCNQ2 K+ channel. Proc. Natl. Acad. Sci. USA (2001) 98:12272–12277.
  • CASTALDO P, DEL GIUDICE EM, COPPOLA G, PASCOTTO A, ANNUNZIATO L, TAGLIALATELA M: Benign familial neonatal convulsions caused by altered gating of KCNQ2/KCNQ3 potassium channels. Neurosci (2002) 22:RC199.
  • MIRAGLIA DEL GIUDICE E, COPPOLA G, SCUCCIMARRA G, CIRILLO G, BELLINI G, PASCOTTO A: Benign familial neonatal convulsions (BFNC) resulting from mutation of the KCNQ2 voltage sensor. Eur.J. Hum. Genet. (2000) 8:994–997.
  • HIROSE S, ZENRI F, AKIYOSHI H et al:A novel mutation of KCNQ3 (c.925T- C) in a Japanese family with benign familial neonatal convulsions. Ann. Neurol. (2000) 47:822–826.
  • LERCHE H, BIERVERT C, ALEKOV AK et al.: A reduced K+ current due to a novel mutation in KCNQ2 causes neonatal convulsions. Ann. Neurol (1999) 46:305–312.
  • SCHROEDER BC, KUBISCH C, STEIN V, JENTSCH TJ: Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy. Nature (1998) 396:687–690.
  • OKADA M, ZHU G, HIROSE S et al: Age-dependent modulation of hippocampal excitability by KCNQ-channels. Epilepsy Res. (2003) 53:81–94.
  • WATANABE H, NAGATA E, KOSAKAI A et al.: Disruption of the epilepsy KCNQ2 gene results in neural hyperexcitability. Neurochem. (2000) 75:28–33.
  • YANG Y, BEYER BJ, OTTO JF et al: Spontaneous deletion of epilepsy gene orthologs in a mutant mouse with a low electroconvulsive threshold. Hum. MM. Genet (2003) 12:975–984.
  • SAGANICH MJ, MACHADO E, RUDY B: Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain.' Neurosci. (2001) 21:4609–4624.
  • YANG WP, LEVESQUE PC, LITTLE WA et al.: Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy. I Biol. Chem. (1998) 273:19419–19423.
  • WANG H-S, PAN Z, SHI W et al.: KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel. Science (1998) 282: 1890-1893.
  • ••First paper to suggest KCNQ2/3 mayrepresent the molecular correlate of the Im.
  • COOPER EC, ALDAPE KD, ABOSCH A et al: Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy. Proc. NatL Acad. Sci. USA (2000) 97:4914–4919.
  • COOPER EC, HARRINGTON E, JAN YN, JAN LY: M Channel KCNQ2 subunits are localized to key sites for control of neuronal network oscillations and synchronization in mouse brain.' Neurosci. (2001) 21:9529–9540.
  • BROWN DA, ADAMS PR: Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neuron. Nature (1980) 283:673–676.
  • HALLI WELL JV, ADAMS PR: Voltage clamp analysis of muscarinic excitation in hippocampal neurons. Brain Res (1982) 250:71–92.
  • MADISON DV, LANCASTER B, NICOLL RA: Voltage clamp analysis of cholinergic action in the hippocampus. Neurosci. (1987) 7:733–741.
  • STORM JF: Potassium currents in hippocampal pyramidal cells. Frog. Brain Res. (1990) 83:161–187.
  • AIKEN SP, LAMPE BJ, MURPHY PA, BROWN BS: Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurons by linopirdine (DuP-996), a neurotransmitter release enhancer. Br.j Pharmacol (1995) 115:1163–1168.
  • LAMAS JA, SELYANKO AA, BROWN DA: Effects of a cognition-enhancer, linopirdine (DuP-996), on M-type potassium currents (IKM) and some other voltage- and ligand-gated membrane currents in rat sympathetic neurons. Ear: Neurosci. (1997) 9:605–616.
  • SCHNEE ME, BROWN BS: Selectivity of linopirdine (DuP-996), a neurotransmitter release enhancer, in blocking voltage-dependent and calcium-activated potassium currents in hippocampal neurons. Pharmacol Exp. Ther., (1998) 286:709–717.
  • ZACZEK R, CHORVAT RJ, SAYA JA et al.: Two new potent neurotransmitter release enhancers, 10,10- bis(4-pyridinylmethy6-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. Pharmacol. Exp. Ther. (1998) 285:724–730.
  • EARL RA, ZAZEK R, TELEHA CA et al.: 2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action. Med. Chem. (1998) 41:4615–4622.
  • RUNDFELDT C: The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur: Pharmacol (1997) 336:243–249.
  • RUNDFELDT C: Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells. Epilepsy Res. (1999) 35:99–107.
  • HETKA R, RUNDFELDT C, HEINEMANN U, SCHMITZ D: Retigabine strongly reduces repetitive firing in rat entorhinal cortex. Eur:j. Pharmacol, (2000) 386:165–171.
  • RUNDFELDT C, NETZER R: The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary cells transfected with human KCNQ2/3 subunits. Neurosci Lett, (2000a) 282:73–76.
  • ••One of three papers showing thatretigabine activates KCNQ2/3 channels.
  • MAIN JM, CRYAN JE, DUPERE JR, COX B, CLARE JJ, BURBRIDGE SA: Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol (2000) 58:253–262.
  • ••One of three papers showing thatretigabine activates KCNQ2/3 channels.
  • WICKENDEN AD, YU W, ZOU A, JEGLA T, WAGONER PK: Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol (2000) 58:591–600.
  • ••One of three papers showing thatretigabine activates KCNQ2/3 channels.
  • TATULIAN L, DELMAS P, ABOGADIE FC, BROWN DA: Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anticonvulsant drug retigabine. NeuroscL (2001) 21:5535–5545.
  • PASSMORE GM, SELYANKO AA, MISTRY M. et al.: KCNQ/M currents in sensory neurons: significance for pain therapy. Neurosci (2003) 23:7227–7236.
  • ••A series of experiments supporting a rolefor KCNQ2/3 channels in pain processing.
  • KAPETANOVIC IM, YONEKAWA WD, KUPFERBERG HJ: The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vivo. Epilepsy Res. (1995) 22:167–173.
  • RUNDFELDT C, ARMAND V, HEINEMANN U: Multiple actions of the new anticonvulsant D-23129 on voltage-gated inward currents and GABA-induced currents in cultured neuronal cells (abstract). Naunyn-Schnnedeberg's Arch. Phannacol (1995) 351 (suppl.):R160.
  • RUNDFELDT C, NETZER R: Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arznehnittelforschung (2000b) 50:1063–1070.
  • ILYIN VI, CARLIN KP, HODGES DD, ROBLEDO S, WOODWARD PM: Flupirtine A positive modulator of heteromeric KCNQ2/Q3 channels. Soc. Neurosci. Abstract. (2002) 758.10.
  • COOK L, NICKOLSON VJ, STEINFELS GE ROHRBACH KW, DENOBLE VJ: Cognition enhancement by the acetylcholine releaser DuP-996. Drug Dev. Res. (1990) 19:301–314.
  • NICKOLSON VJ, TAM SW, MEYERS MJ, COOK L: DuP-996 (3,3-bis(4-pyrindinylmethyl)-1-phenylindolin-2-one) enhances the stimulus-induced release of acetylcholine from rat brain in vitro and in vivo. Drug Dev. Res. (1990) 19:285–300.
  • ZAZEK R, SAYDOFF J: Depolarization activated releasers of transmitters as therapeutics for dementia: preclinical characterization of linopirdine (DuP-996). Curr: Opin. Invest. Drugs, (1993) 2:1097–1104.
  • FLAGMEYER I, GEBERT I, VAN DER STAAY FJ: General pharmacology of the putative cognition enhancer linopirdine. Arznehnittelforschung (1995) 45:456–459.
  • ARMAND V, RUNDFELDT C, HEINEMANN U: Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn-SchinialebergS Arch. Phannacol (1999) 359:33–39.
  • DOST R, RUNDFELDT C: The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca2+ and low Mg2+ model in the hippocampal slice preparation. Epilepsy Res. (2000) 38:53–66.
  • NIKEL B, SHANDRA AA, GODLEVSKY LS, MAZARATI AM, KUPFERBERG HJ SZELENYI I: Anticonvulsant activity of D-20443 (abstract). Naunyn-SchrniedebergS Arch. Phannacol (1993a) 347(suppl.):R142.
  • NIKEL B, SHANDRA AA, GODLEVSKY LS, MAZARATI AM, KUPFERBERG HJ SZELENYI I: Anticonvulsant activity of a new drug D-20443 (abstract). Epilepsia (1993b) 34(suppl.):S95.
  • ROSTOCK A, TOBER C, RUNDFELDT C et al: D-23129: a new anticonvulsant with broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. (1996) 23:211–223.
  • DAILEY JW, CHEONG JH, KO KH, ADAMS-CURTIS LE, JOBE PC: Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response. Neurosci. Lett. (1995) 195:77–80.
  • TOBER C, ROSTOCK A, RUNDFELDT C, BARTSCH R: D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur.j Phannacol (1996) 303:163–169.
  • PORTER AJ, GRATZ E, NARANG PK et al.: Effect of flupirtine on uncontrolled partial or absence seizures. Epilepsia (1983) 24:253–254
  • BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E: Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. (2002) 51:31–71.
  • BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E: Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. (2001) 43:11–58.
  • FERRON GA, PAUL J, FRUNCILLO R et al.: Multiple-dose, linear, dose-proportional kinetics of retigabine in healthy volunteers. Clin. Phannacol, (2002) 42:175–182.
  • SHERIDAN PH, SEAMAN CA, NARANG PK et al.: Pilot study of flupirtine in refractory seizures. Neurology (abstract) (1986) 36(Suppl.):85.
  • WICKENDEN AD, YE F, LIU Y, MCNAUGHTON-SMITH G, ROELOFFS R, RIGDON GC: KCNQ channel expression in rat DRG following nerve ligation Soc. Neurosci. Abstract. (2002) 454.7.
  • KIM DS, CHOI JO, RIM HD, CHO HJ: Downregulation of voltage-gated potassium channel alpha gene expression in dorsal root ganglia following chronic constriction injury of the rat sciatic nerve. Brain Res. Ma Brain Res. (2002) 105:146–152.
  • ABDULLA FA, SMITH PA; Axotomy- and autotomy-induced changes in Ca2+ and K+ channel currents of rat dorsal root ganglion neurons. Neurophysiol. (2001) 85:644–658
  • EVERILL B, KOCSIS JD: Reduction in potassium currents in identified cutaneous afferent dorsal root ganglion neurons after axotomy. Neurophysiol (1999) 82:700–708
  • ISHIKAWA K, TANAKA M, BLACK JA, WAXMAN SG: Changes in expression of voltage-gated potassium channels in dorsal root ganglion neurons following axotomy. Muscle Nerve. (1999) 22:502–507.
  • BLACKBURN-MUNRO G, JENSEN BS: The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur: Phannacol (2003) 460:109–116.
  • ••A series of behavioural studies supporting arole for KCNQ2/3 channels in pain processing.
  • ROSTOCK A, RUNDFELDT C, BARTSCH R: Effects of the anticonvulsant retigabine in neuropathic pain models in rats. Deutschen Gesellschaft I experimentelle u klinische Phannakologie u Toxikologie (2000) 54:A382.
  • CARLSSON KH, JURNA I: Depression byflupirtine, a novel analgesic agent, of motor and sensory responses of the nociceptive system in rat spinal cord. Eur. Phannacol (1987) 143:89–99.
  • LUBEN V, MULLER H, LOBISCH M, WORZ R: Treatment of tumour pain with flupirtine. Results of a double-blind study versus tramadol. Fortschr. Med. (1994) 112:282–286.
  • SCHEEF W: Analgesic efficacy and safetyof oral flupirtine in the treatment of cancer pain. Postgrad. Med. 1 (1987) 63 (Supp1.3):67–70.
  • SCHEEF W, WOLF-GRUBER D: Flupirtine in patients with cancer pain. Arzneimittelforschung (1985) 35:75–77.
  • MASTRONARDI P, D'ONOFRIO M, SCANNI E, PINTO M et al: Analgesic activity of flupirtine maleate: a controlled double-blind study with diclofenac sodium in orthopaedics. J. Int. Med. Res. (1988) 16:338–348.
  • REITHMULLER-WINZEN H: Flopictine in the treatment of postoperative pain. Postgrad. Med. (1987) 63\(Supp1.3):61–65.
  • CECCARELLI G, CIAMPINI M, FRONTESPEZI S: Flopictine: the first Italian experience. Postgrad. Med..]: (1987) 63 (Supp1.3):105–108.
  • MOORE RA, BULLINGHAM RE, SIMPSON S et al.: Comparison of flupirtine maleate and dihydrocodeine in patients following surgery. Br. I Anaesth. (1983) 55:429–432.
  • HERMANN WM, KERN U, AIGNER M: On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing 12-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. Postgrad. Med. J. (1987) 63\(Supp1.3):87–103.
  • RAFFA RB, FRIDERICHS E, REIMANN W, SHANK RB, CODD EE, VAUGHT JL: Opioid and non-opioid components independently contribute to the mechanism of action of tramadol, an atypical opioid analgesic. J. Pharinacol. Exptl. Ther. (1992) 260:275–285.
  • MILLION R, FINLAY BR, WHITTINGTON JR: Clinical trial of flupirtine maleate in patients with migraine. Current Med. Res. Opin. (1984) 9:204–212.
  • MCMAHON FG, ARNDT WF JR, NEWTON JJ, MONTGOMERY PA, PERHACH JL: Clinical experience with flupirtine in the US. Postgrad. Med. (1987) 63\(Supp1.3):81–85.
  • FRIEDEL HA, FITTON A: Flopictine. A review of its pharmacological properties and therapeutic efficacy in pain states. Drugs (1993) 45:548–69.
  • JAKOB R, KRIEGLSTEIN J: Influence of flupirtine on a G protein coupled inwardly rectifying potassium current in hippocampal neurons. Br. J. Pharinacol. (1997) 122:1333–1338.
  • KORNHUBERJ, BLEICH S, WILTFANG J, MALER M, PARSONS CG: Flopictine shows functional NMDA antagonism by enhancing Mg2+ block via activation of voltage-independent potassium channels. J. Neural Trauma. (1999) 106:857–867.
  • SCHRODER RL, JESPERSEN T, CHRISTOPHERSEN P, STROBAEK D, JENSEN BS, OLESEN S-P: KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology (2001) 40:888–898.
  • GRIBKOFF VK, STARRETT JE, DWORETZKY SI et al.: Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. (2001) 7:471–477.
  • WU Y-J, BOISSARD CG, GRECO C et al.: (5) N [1 (3 Morpholin-4-ylphenyl)ethyl]-3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. j. Med. Chem. (2003) 46:3197–3200.
  • WU Y-J, DAVIS CD, DWORETZKY S et al.: Fluorine substitution can block CYP3A4 metabolism-dependent inhibition (MDI): identification of (.9 N [1 ( 4 fluoro-3-morpholin-4-ylphenyl)ethyl]-3-(4-fluorophenyOacrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 MM.,/ Med. Chem. (2003) 46:3778–3782.
  • RONEN GM ROSALES TO, CONNOLLY M, ANDERSON VE, LEPPERT M: Seizure characteristics in chromosome 20 benign familial neonatal convulsions. Neurology (1993) 43:1355–1360.
  • MARRION NV: Control of M-currrent.Ann. Rev Physiol (1997) 59:483–504.
  • GUTMAN GA CHANDY KG, ADELMAN JP et al. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol . Rev (2003) 55(4):583–586.
  • LERCHE C, SCHERER CR, SEEBOHM G et al: Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity. J. Biol. Chem. (2000) 275:22395–22400.
  • SCHROEDER BC, HECHENBERGER M, VVEINREICH F, KUBISCH C, JENTSCH TJ: KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J. Biol. Chem. (2000) 275:24089–24095.
  • KHARKOVETS T, HARDELIN JP, SAFIEDDINE S et al: KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc. Natl. Acad. Sci. USA (2000). 97:4333–4338.
  • JENTSCH TJ. Neuronal KCNQ potassium channels: physiology and role in disease. Nature Rev. Neurosci. (2000) 1:21–30.
  • GRIBKOFF VK. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin. Ther. Targets(2003) 7(6):737–748.
  • WICKENDEN AD, ZOU A, WAGONER PK, JEGLA T: Characterization of KCNQ5/3 potassium channels expressed in mammalian cells. Br. Pharmacol (2001) 132:381–384.
  • YUS-NAJERA E, MUNOZ A, SALVADOR N et al.: Localization of KCNQ5 in the normal and epileptic human temporal neocortex and hippocampal formation. Neuroscience (2003) 120(2):353–364.
  • RIVERA-ARCONADA I, MARTINEZ-GOMEZ J, LOPEZ-GARCIA JA. M-Current modulators alter rat spinal nociceptive transmission: an electrophysiological study M vitro. Neuropharmacology (2004) 46(4):598–606.
  • DEVAUX JJ, KLEOPA KA, COOPER EC, SCHERER SS: KCNQ2 is a nodal K± channel. Neurosci (2004) 24(5):1236–1244.
  • DEDEK K, KUNATH B, KANANURA C, REUNER U, JENTSCH TJ, STEINLEIN OK: Myokymia and neonatal epilepsy caused by a mutation in the voltage sensor of the KCNQ2 K± channel. Proc. Nati Acad. Sci. USA (2001) 98(21):12272–12277.
  • HUNT SP, MANTYH PW: The molecular dynamics of pain control. Nat. Rev Neurosci. (2001) 2(2):83–91.

Websites

  • http://www.iasp-pain.org/pubsopen.html International Association for the Study of Pain website, publications page

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.